Differential characteristics of two newly established human breast carcinoma cell lines. 1985

M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi

Two human breast carcinoma cell lines, EP and MW, were established in culture from malignant pleural effusions. In addition to producing tumors in antithymocyte serum-immunosuppressed mice, both cell lines showed epithelial characteristics and anchorage-independent growth in soft agar. EP and MW differed in morphology (spindle-shaped versus round), chromosomal mode (hyperdiploid versus near triploid), estrogen receptor content (43.8 versus 5.1 fmol/mg protein), cloning efficiency (0.24 versus 15%), and activities (milliunits/10(6) cells) of creatine phosphokinase (25.7 versus 62.6) and lactate dehydrogenase (346.7 versus 778.5). Electron microscopy revealed that MW cells had more perinuclear filamentous material and more frequent intracytoplasmic vacuole formation than did EP cells. While having no effect on MW cells at the concentrations studied (10(-5) to 10(-11) M), beta-estradiol (10(-7) M) stimulated the growth of EP cells by 106% over the hormone-depleted control. In a variety of systems, EP was consistently the more drug sensitive of the two lines. In vitro, EP was significantly (p less than 0.001) more sensitive to methotrexate, vincristine, and 5-fluorouracil, respectively. In antithymocyte serum-mouse xenografts, EP displayed a greater response to three different dosages of a combination of cyclophosphamide, methotrexate, and 5-fluorouracil. One such dosage (cyclophosphamide, 32.0 mg/kg/day; methotrexate, 13.0 mg/kg/day; 5-fluorouracil, 190.0 mg/kg/day; for 1 day) reduced EP and MW tumor weights to 5.9 and 41% of controls, respectively. These results correlated well with the clinical responses.

UI MeSH Term Description Entries
D007527 Isoenzymes Structurally related forms of an enzyme. Each isoenzyme has the same mechanism and classification, but differs in its chemical, physical, or immunological characteristics. Alloenzyme,Allozyme,Isoenzyme,Isozyme,Isozymes,Alloenzymes,Allozymes
D007770 L-Lactate Dehydrogenase A tetrameric enzyme that, along with the coenzyme NAD+, catalyzes the interconversion of LACTATE and PYRUVATE. In vertebrates, genes for three different subunits (LDH-A, LDH-B and LDH-C) exist. Lactate Dehydrogenase,Dehydrogenase, L-Lactate,Dehydrogenase, Lactate,L Lactate Dehydrogenase
D001943 Breast Neoplasms Tumors or cancer of the human BREAST. Breast Cancer,Breast Tumors,Cancer of Breast,Breast Carcinoma,Cancer of the Breast,Human Mammary Carcinoma,Malignant Neoplasm of Breast,Malignant Tumor of Breast,Mammary Cancer,Mammary Carcinoma, Human,Mammary Neoplasm, Human,Mammary Neoplasms, Human,Neoplasms, Breast,Tumors, Breast,Breast Carcinomas,Breast Malignant Neoplasm,Breast Malignant Neoplasms,Breast Malignant Tumor,Breast Malignant Tumors,Breast Neoplasm,Breast Tumor,Cancer, Breast,Cancer, Mammary,Cancers, Mammary,Carcinoma, Breast,Carcinoma, Human Mammary,Carcinomas, Breast,Carcinomas, Human Mammary,Human Mammary Carcinomas,Human Mammary Neoplasm,Human Mammary Neoplasms,Mammary Cancers,Mammary Carcinomas, Human,Neoplasm, Breast,Neoplasm, Human Mammary,Neoplasms, Human Mammary,Tumor, Breast
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004958 Estradiol The 17-beta-isomer of estradiol, an aromatized C18 steroid with hydroxyl group at 3-beta- and 17-beta-position. Estradiol-17-beta is the most potent form of mammalian estrogenic steroids. 17 beta-Estradiol,Estradiol-17 beta,Oestradiol,17 beta-Oestradiol,Aerodiol,Delestrogen,Estrace,Estraderm TTS,Estradiol Anhydrous,Estradiol Hemihydrate,Estradiol Hemihydrate, (17 alpha)-Isomer,Estradiol Monohydrate,Estradiol Valerate,Estradiol Valeriante,Estradiol, (+-)-Isomer,Estradiol, (-)-Isomer,Estradiol, (16 alpha,17 alpha)-Isomer,Estradiol, (16 alpha,17 beta)-Isomer,Estradiol, (17-alpha)-Isomer,Estradiol, (8 alpha,17 beta)-(+-)-Isomer,Estradiol, (8 alpha,17 beta)-Isomer,Estradiol, (9 beta,17 alpha)-Isomer,Estradiol, (9 beta,17 beta)-Isomer,Estradiol, Monosodium Salt,Estradiol, Sodium Salt,Estradiol-17 alpha,Estradiol-17beta,Ovocyclin,Progynon-Depot,Progynova,Vivelle,17 beta Estradiol,17 beta Oestradiol,Estradiol 17 alpha,Estradiol 17 beta,Estradiol 17beta,Progynon Depot
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D014410 Tumor Stem Cell Assay A cytologic technique for measuring the functional capacity of tumor stem cells by assaying their activity. It is used primarily for the in vitro testing of antineoplastic agents. Clonogenic Cell Assay, Tumor,Colony-Forming Units Assay, Tumor,Neoplasm Stem Cell Assay,Stem Cell Assay, Tumor,Colony Forming Units Assay, Tumor

Related Publications

M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
July 1998, International journal of cancer,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
January 2002, Anticancer research,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
December 1987, Cancer research,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
May 1990, Cancer research,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
October 1982, Cancer,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
March 1984, Journal of the National Cancer Institute,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
February 1996, Cancer genetics and cytogenetics,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
January 1986, British journal of cancer,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
November 1989, Cancer research,
M Y Chu, and M G Hagerty, and M C Wiemann, and L M Tibbetts, and S Sato, and F J Cummings, and H A Bogaars, and E H Leduc, and P Calabresi
June 1993, Laboratory investigation; a journal of technical methods and pathology,
Copied contents to your clipboard!